TL;DR: A Drug Enforcement Administration administrative law judge formally set the hearing schedule for cannabis rescheduling proceedings today, June 25, signaling that the multi-year regulatory odyssey toward Schedule III classification is entering its most decisive phase. The DEA judge declined to expand the participant list, narrowing the adversarial process to already-qualified parties. Cannabis equities, as measured by the AdvisorShares Pure US Cannabis ETF (MSOS), are holding near their 2026 year-to-date highs as institutional investors price in the probability of a favorable outcome.
Market Analysis
The MSOS ETF reached its highest level of 2026 in early June, touching approximately $5.75 and sustaining those gains through mid-month as the hearing timeline crystallized. The sector-wide rally reflects a meaningful repricing of regulatory risk across the multi-state operator (MSO) universe. Green Thumb Industries (GTBIF) and Curaleaf Holdings (CURLF/CURLD) have both appreciated meaningfully off their 52-week troughs, with GTBIF continuing to demonstrate the balance-sheet resilience that has made it a benchmark holding among cannabis-focused institutional portfolios.
Canadian licensed producers have experienced a more muted response. Canopy Growth (CGC) and Tilray Brands (TLRY) remain structurally constrained by the Schedule III pathway’s primary benefit accruing to U.S.-touching operators. Organigram (OGI), however, has attracted incremental attention given its deepened U.S. partnerships and potential downstream exposure to an expanded American market.
The DEA judge’s decision to close the participant list is analytically significant. A narrower, more focused hearing reduces procedural drag and decreases the probability of protracted litigation from prohibitionist intervenors. Market participants watching the cannabis stock tracker should note that hearing schedule clarity historically correlates with reduced implied volatility in MSOS options, which may attract fresh covered-call writing and range-bound institutional accumulation strategies.
Regulatory Backdrop
The rescheduling process was initiated following HHS’s August 2023 recommendation that cannabis be moved from Schedule I to Schedule III. The DEA formally proposed the rule change in May 2024, but administrative law hearings — required when qualified parties object — have extended the timeline by years. The hearing schedule now set by the administrative law judge provides, for the first time, a structured endpoint to what had been an open-ended procedural calendar.
Schedule III reclassification would not legalize cannabis at the federal level, but would eliminate the punitive Section 280E tax treatment that currently bars cannabis businesses from deducting ordinary business expenses. Industry analysts estimate effective tax rate reductions of 30 to 50 percentage points for operators such as Green Thumb and Trulieve Cannabis, directly converting into free cash flow generation at scale.
The DEA’s refusal to expand the participant list is being interpreted as a signal that the administrative process will not be weaponized for indefinite delay. Anti-legalization advocacy organizations that sought to intervene were not granted standing, which removes one of the more unpredictable tail risks from the timeline.
Forward-Looking Assessment
The cannabis sector faces a binary but increasingly time-bounded catalyst. If the rescheduling hearing proceeds on the newly established schedule and results in a favorable administrative ruling, the regulatory and financial architecture of the U.S. cannabis industry will be permanently altered. The near-term implication is continued sector support at or near 2026 highs, with momentum-driven upside contingent on hearing progress milestones.
Investors should maintain appropriate position sizing. The administrative hearing process remains subject to judicial review, and any adverse ruling — or a court-ordered pause — would likely result in sharp sector-wide selling. The risk/reward for well-capitalized MSOs with demonstrated profitability and strong retail footprints remains compelling through the balance of 2026, but headline risk is elevated and position management discipline is essential.